Mount Sinai Innovation Partners Mount Sinai Innovation Partners Mount Sinai Innovation Partners Mount Sinai Innovation Partners
  • Get Started
    • Disclose a Technology
    • Request an Agreement
    • Search Technologies
    • Contact Your Representative
  • About Us
    • Our Mission
    • Our Impact
      • Technologies
      • Startup Companies
    • Our Team
    • Our Partners
  • Programs
    • Elementa Labs
    • Entrepreneurship Program
    • Fellows Program
    • i3 Funding
      • i3 Prism
      • i3 Genesis
      • i3 Accelerator
    • External Collaborations
  • Resources
    • Innovation Guide
    • Drug Discovery Guide
    • Local Resources
    • Institutional Policies
    • Frequently Asked Questions (FAQs)
  • Discover More
    • News
    • Events
    • Videos
  • Careers
    • Explore Career Opportunities
  • Mount Sinai Health System
    • MountSinai.org
    • Search Faculty
    • Clinical Trials
    • Donations & Gifts
    • Faculty Consulting
Diagnostic

GENE-SIGNATURE FOR DIAGNOSIS OF EARLY HEPATOCELLULAR CARCINOMA

September 22, 2015

The incidence of hepatocellular carcinoma (HCC) is 750,000 new cases globally, it is the second leading cause of cancer-related death and represents a major health problem. When identified at early stages, curative treatments such as resection, transplantation and percutaneous ablation are feasible. …

Read full post
Therapeutic

HYBRID FUSION PROTEIN TRANSCRIPTION REGULATOR – A NOVEL ANTIVIRAL THERAPY

September 21, 2015

Background: Two families of transcriptional regulators, members of the “signal transducers and activators of transcription” (STAT) and “interferon regulatory factor” (IRF) families, work in conjunction to establish a cascade of gene regulation and signal transduction events that lead to transcriptional activation of …

Read full post
Diagnostic

IDENTIFYING THE SUBTYPES OF LEUKEMIA BY CHARACTERIZING THE MUTATIONS OF THE PTPN11 GENE

February 25, 2015

Intracellular signaling pathways mediate cellular responses to a variety of extracellular signals and dysregulation of such pathways, especially those involved in cell growth and differentiation, is the main cause of cancer. The RAS family of proteins plays key roles in signal transduction, …

Read full post
Therapeutic

EXPANDED CORD BLOOD STEM CELLS FOR USE AS TRANSPLANTATION GRAFTS

July 31, 2014

Scientists in Drs. Hoffman and Chaurasia’s laboratories have developed a novel approach to substantially expand the numbers of functional Cord blood (CB) hematopoietic stem cells (HSCs) while maintaining true stem cell engraftment capability. Cord blood (CB) cells that express CD34 have extensive …

Read full post
Research

NOVEL HIGH THROUGHPUT SCREEN TO IDENTIFY REGULATORS OF UBIQUITIN LIGASE ACTIVITY

May 29, 2014

Protein ubiquitination, a multi-step process utilizing a cascade of three enzyme classes (E1, E2 and E3), tightly regulates cellular protein turnover. It plays a key role in cellular proliferation and inflammation and is associated with a multitude of diseases, including cancer, metabolic …

Read full post
Therapeutic

LOW DOSE PROTEASOME INHIBITOR SENSITIZES PI3K RESISTANT CANCERS TO TREATMENT WITH PI3K PATHWAY INHIBITORS

May 29, 2014

Resistance to PI3 kinase pathway inhibitors can occur through changes in cancer signaling pathways. “Priming” with subtherapeutic doses bortezomib leads to activation of and reliance on the PI3 kinase pathway, making cancers susceptible to PI3 kinase pathway inhibitors. Dr. Ross Cagan and members …

Read full post
Diagnostic

MODIFIED VERO CELLS WITH SUPPRESSED INNATE IMMUNE RESPONSES AND ENHANCED VIRUS PRODUCTION

May 12, 2014

Dr. Chris Basler and colleagues have developed a stable cell line with enhanced virus replication and production efficiency. The Vero 76 cell line (ATCC No. CCL-1587) has been widely used for cell-based research and product development (1, 2, 4). Several characteristics of …

Read full post
Therapeutic

NOVEL BROMODOMAIN (BRD4) SMALL MOLECULE INHIBITORS FOR TARGETED TREATMENT OF CANCER

April 25, 2014

Bromodomain-containing proteins function as chromatin modifiers and mediators of protein-protein interactions, controlling gene expression.  BRDs have been functionally implicated in numerous disease processes, including cancer, and small molecule inhibitors have been developed with some advancing to early clinical trials in cancer. BRD4 …

Read full post

Mount Sinai Health System

The Mount Sinai Health System is an integrated health care system providing exceptional medical care to our local and global communities.

Read More

Contact MSIP

MSIPInfo@mssm.edu

For technology and research inquiries: visit Contact Your Representative or Contact MSIP

 

Follow Us

  • LinkedIn
  • Facebook
  • X
  • YouTube

Stay Updated

Sign up for the MSIP mailing list

Mount Sinai Innovation Partners © Copyright 2025

  • Privacy Policy
  • Terms & Conditions
  • Non-Discrimination Notice
  • Get Started
    • Disclose a Technology
    • Request an Agreement
    • Search Technologies
    • Contact Your Representative
  • About Us
    • Our Mission
    • Our Impact
      • Technologies
      • Startup Companies
    • Our Team
    • Our Partners
  • Programs
    • Elementa Labs
    • Entrepreneurship Program
    • Fellows Program
    • i3 Funding
      • i3 Prism
      • i3 Genesis
      • i3 Accelerator
    • External Collaborations
  • Resources
    • Innovation Guide
    • Drug Discovery Guide
    • Local Resources
    • Institutional Policies
    • Frequently Asked Questions (FAQs)
  • Discover More
    • News
    • Events
    • Videos
  • Careers
    • Explore Career Opportunities
  • Mount Sinai Health System
    • MountSinai.org
    • Search Faculty
    • Clinical Trials
    • Donations & Gifts
    • Faculty Consulting

Hit enter to search or ESC to close